Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and ...

Dr. Dolsten was most recently CSO of Pfizer and has served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals Appointment follows the transition ...

Mighty tomes, deep dives and fresh perspectives — the most eagerly awaited volumes being trailed by art-world publishers focus on subjects including the still-life painter Clara Peeters, Andrew Wyeth, ...

One Indian pharmaceutical company dey manufacture unlicensed, highly addictive opioids and dey export dem illegally to West Africa wia dem dey drive a major public health crisis for countries ...

Dr. Reddy’s Laboratories fell 5.8% to Rs 1,128.90, while Zydus Lifesciences dropped 4.8%. Sun Pharma, India's largest drugmaker, declined by 3.2% to Rs 1,647.35, becoming the top loser on the BSE ...

Trump told reporters on Tuesday that sectoral tariffs on pharmaceuticals and semiconductor chips would also start at "25 per cent or higher, and it will go very substantially higher over the ...

President Trump told reporters in Mar-a-lago that he was considering tariffs of 25% or more on automobiles, semiconductors and pharmaceutical products. Photo: Press Pool WASHINGTON—President ...

Feb 19 (Reuters) - An index of Indian pharmaceutical company shares (.NIPHARM), opens new tab slid 2% to its lowest level in seven months on Wednesday after U.S. President Donald Trump said he ...

Trump says he will reveal more about 25% autos duty on April 2 Pharma, chip firms may face tariffs above 25%, timing uncertain EU trade chief to meet with US officials on Wednesday Auto industry ...

The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market may have registered losses on Friday ...

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...